These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 291484)

  • 41. Marginal excision for osteosarcoma with caffeine assisted chemotherapy.
    Tsuchiya H; Tomita K; Mori Y; Asada N; Yamamoto N
    Clin Orthop Relat Res; 1999 Jan; (358):27-35. PubMed ID: 9973973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma.
    Longhi A; Pignotti E; Versari M; Asta S; Bacci G
    Oncol Rep; 2003; 10(1):151-5. PubMed ID: 12469162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.
    Rosen G; Nirenberg A
    Cancer Treat Rep; 1982 Sep; 66(9):1687-97. PubMed ID: 6981454
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.
    Wagener DJ; van Oosterom AT; Mulder JH; Somers R; Mouridsen HT; Cortes Funes H; Thomas D; Sylvester R
    Cancer Treat Rep; 1986 May; 70(5):615-8. PubMed ID: 3458532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
    Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.
    Yagoda A; Watson RC; Gonzalez-Vitale JC; Grabstald H; Whitmore WF
    Cancer Treat Rep; 1976 Jul; 60(7):917-23. PubMed ID: 1009522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
    Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
    Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
    [No Abstract]   [Full Text] [Related]  

  • 50. [Developments in the treatment of osteosarcoma since 1979. Report of the statistics at the Centre Léon-Bérard].
    Brunat-Mentigny M; Biron P; Kohler R; Blondet R; Bérard J; Chauvot P; Bouffet E; Carret JP; Jonas P; Patricot LM
    Bull Cancer; 1990; 77(9):933-40. PubMed ID: 2224166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Experience with and outlook for the use of cisplatin in the combined therapy of osteogenic sarcoma].
    Trapeznikov NN; Gorbunova VA; Erëmina LA; Siniukov PA; Kovalevskiĭ EE
    Vopr Onkol; 1987; 33(7):65-74. PubMed ID: 3475857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.
    Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Gorlick R; Doski JJ; Womer RB; Janeway KA
    Pediatr Blood Cancer; 2016 Feb; 63(2):370-1. PubMed ID: 26376351
    [No Abstract]   [Full Text] [Related]  

  • 54. Intra-arterial cis-platinum in osteosarcoma.
    Carrasco CH; Charnsangavej C; Richli WJ; Wallace S
    Haematol Blood Transfus; 1987; 31():52-6. PubMed ID: 3327785
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cis-dichlorodiammineplatinum, a representative of a new group of cytostatic drugs].
    Janas J
    Nowotwory; 1981; 31(3-4):251-6. PubMed ID: 7045812
    [No Abstract]   [Full Text] [Related]  

  • 56. Cisplatin and renal magnesium wasting.
    Winkler CF; Mahr MM; DeBandi H
    Ann Intern Med; 1979 Sep; 91(3):502-3. PubMed ID: 475203
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase II window studies: 10 years of experience and counting.
    Smith MA; Anderson B
    J Pediatr Hematol Oncol; 2001; 23(6):334-7. PubMed ID: 11563765
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical pharmacology of cis-diamminedichloroplatinum and its value in the chemotherapy of neoplasms].
    Robak T; Płuzańska A
    Pol Arch Med Wewn; 1983 Jan; 69(1):59-67. PubMed ID: 6351029
    [No Abstract]   [Full Text] [Related]  

  • 59. Response of the murine gastrointestinal epithelium to cis-dichlorodiammineplatinum. II: radiation combinations.
    Burholt DR; Schenken LL; Kovacs CJ; Hagemann RF
    Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1377-81. PubMed ID: 575124
    [No Abstract]   [Full Text] [Related]  

  • 60. [Ⅲ. Early Phase Drug Development and Precision Medicine for Osteosarcoma].
    Iwata S
    Gan To Kagaku Ryoho; 2021 Mar; 48(3):351-355. PubMed ID: 33790156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.